ロタウイルス・ワクチン(Rotavirus vaccines):ワクチンのグローバル市場機会分析...市場調査レポートについてご紹介

【英文タイトル】MarketVIEW: Rotavirus vaccines
Global vaccine commercial opportunity assessment

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

★目次PDFファイル⇒http://h-and-i.main.jp/market-report/Vaczine/VAMV057_TOC_2004.pdf

****This product is composed of a model and summary presentation

【Contents – Summary presentation (MS PowerPoint based)】

Authors Note
Executive summary
Commercial model: key outputs
Rotavirus vaccines: global forecast revenue ($m) to 2030
Rotavirus vaccines: global forecast volume (000s doses) to 2030
Rotavirus vaccines: volume (000s doses) by country and vaccine – Major Western to 2030
Rotavirus vaccines: revenue ($m) by country and vaccine – Major Western to 2030
Rotavirus vaccines: volume (000s doses) by country and vaccine – BRICMIT to 2030
Rotavirus vaccines: revenue ($m) by country and vaccine – BRICMIT to 2030
Rotavirus vaccines: volume (000s doses) by WHO region and vaccine – GAVI to 2030
Rotavirus vaccines: revenue ($m) by WHO region and vaccine – GAVI to 2030
Rotavirus vaccines: market share by country and region in 2020*
Rotavirus vaccines: market share (volume and value) by vaccine in 2020*
Rotavirus vaccines: volume and revenue breakdown of ‘Other’ vaccines to 2030
Rotavirus: disease background and epidemiology
Rotavirus: the pathogen
Rotavirus transmission
Rotavirus diarrhoea
Protective immunity against rotavirus infection
Rotavirus: prevalence and incidence worldwide
Mortality associated with rotavirus
The global burden of RV diarrhoeal disease
Countries with the highest burden of RV-related deaths
Rotavirus: at-risk groups
Age distribution of rotavirus infections in children aged <5 years, 2000–2011, England and Wales Prevention of RV disease Rotavirus vaccines: the current products and markets Rotarix (GSK) RotaTeq (Merck & Co) WHO guidelines on rotavirus vaccination National immunisation programmes – USA, Canada, Australia National immunisation programmes – 5EU National immunisation programmes – BRIC and MINT countries GAVI-supported RV vaccine introductions by WHO region: 26 countries National RV vaccine introductions by WHO region: 59 countries. Coverage of national vaccination programmes. New rotavirus vaccines: overview of current R&D The need for new rotavirus vaccines Rotavirus vaccine: ideal target product profiles Live rotavirus vaccines in development Non-replicating rotavirus vaccines Rotavirus vaccines: Modelling the current market Modelling methodology: overview New product launch assumptions Model inputs – USA, Canada, Australia Model inputs – 5EU Model inputs – BRIC Model inputs – MINT Model inputs – GAVI countries WHO regions (as used in GAVI models) Bibliography Disclaimer About VacZine Analytics ※PAGES: 65 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form 【Contents – Vaccine demand model(s) (MS Excel-based) – 1 model】 Title sheet CHARTS – global CHARTS – major Western (5EU +3) CHARTS – BRICMIT CHARTS – GAVI MS by country or region MS by vaccine MS other Vol Val global Vol Val 5EU+3 Vol Val GAVI US Canada United Kingdom France Germany Italy Spain Australia Brazil Russia. India. China Mexico Indonesia. Turkey GAVI Africa GAVI AMR + EMR GAVI EUR+SEAR+WPR Birth cohorts Infant mortality Assumptions Backpage ※WORKSHEETS: ~30


【レポート販売概要】

■ タイトル:ロタウイルス・ワクチン(Rotavirus vaccines):ワクチンのグローバル市場機会分析
■ 英文:MarketVIEW: Rotavirus vaccines
Global vaccine commercial opportunity assessment
■ 発行日:2014年6月
■ 調査会社:VacZine Analytics
■ 商品コード:VAMV057-2014
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。